These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24947187)

  • 1. CSNK1E/CTNNB1 are synthetic lethal to TP53 in colorectal cancer and are markers for prognosis.
    Tiong KL; Chang KC; Yeh KT; Liu TY; Wu JH; Hsieh PH; Lin SH; Lai WY; Hsu YC; Chen JY; Chang JG; Shieh GS
    Neoplasia; 2014 May; 16(5):441-50. PubMed ID: 24947187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma.
    Chang JG; Chen CC; Wu YY; Che TF; Huang YS; Yeh KT; Shieh GS; Yang PC
    Oncotarget; 2016 Nov; 7(45):73664-73680. PubMed ID: 27655641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.
    Wangefjord S; Brändstedt J; Lindquist KE; Nodin B; Jirström K; Eberhard J
    Diagn Pathol; 2013 Jan; 8():10. PubMed ID: 23337059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutations, expression and interaction networks in human cancers.
    Wang X; Sun Q
    Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
    Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
    J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between KIAA1199 overexpression and tumor invasion, TNM stage, and poor prognosis in colorectal cancer.
    Xu J; Liu Y; Wang X; Huang J; Zhu H; Hu Z; Wang D
    Int J Clin Exp Pathol; 2015; 8(3):2909-18. PubMed ID: 26045799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
    Baba Y; Nosho K; Shima K; Goessling W; Chan AT; Ng K; Chan JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):822-31. PubMed ID: 20200425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP24A1 is a potential biomarker for the progression and prognosis of human colorectal cancer.
    Sun H; Wang C; Hao M; Sun R; Wang Y; Liu T; Cong X; Liu Y
    Hum Pathol; 2016 Apr; 50():101-8. PubMed ID: 26997443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational analysis of TP53 vs. CTNNB1 mutations in hepatocellular carcinoma suggests distinct cancer subtypes with differential gene expression profiles and chromatin states.
    Biterge Süt B
    Comput Biol Chem; 2020 Dec; 89():107404. PubMed ID: 33096424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Expressions of CUL4A and TP53 in Colorectal Cancer Predict Poor Survival.
    Li C; Bu J; Liao Y; Zhang J; Han J; Zhang H; Xing H; Li Z; Wu H; Liang L; Wang M; Qin W; Yang T
    Cell Physiol Biochem; 2018; 51(6):2829-2842. PubMed ID: 30562757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The majority of β-catenin mutations in colorectal cancer is homozygous.
    Arnold A; Tronser M; Sers C; Ahadova A; Endris V; Mamlouk S; Horst D; Möbs M; Bischoff P; Kloor M; Bläker H
    BMC Cancer; 2020 Oct; 20(1):1038. PubMed ID: 33115416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer.
    Kim KM; Ahn AR; Park HS; Jang KY; Moon WS; Kang MJ; Ha GW; Lee MR; Chung MJ
    BMC Cancer; 2022 Aug; 22(1):940. PubMed ID: 36045334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data.
    Ye H; Zhang X; Chen Y; Liu Q; Wei J
    Oncotarget; 2016 Aug; 7(34):55352-55367. PubMed ID: 27438146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening and computational analysis of colorectal associated non-synonymous polymorphism in CTNNB1 gene in Pakistani population.
    Razak S; Bibi N; Dar JA; Afsar T; Almajwal A; Parveen Z; Jahan S
    BMC Med Genet; 2019 Nov; 20(1):171. PubMed ID: 31699039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the p53 codon 72 polymorphism with clinicopathological characteristics of colorectal cancer through mRNA analysis.
    De Oliveira LP; López I; Dos Santos EM; Tucci P; Marín M; Soares FA; Rossi BM; Coudry Rde A
    Oncol Rep; 2014 Mar; 31(3):1396-406. PubMed ID: 24366026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of altered expression and activity levels of CK1δ and ɛ on tumor growth and survival of colorectal cancer patients.
    Richter J; Ullah K; Xu P; Alscher V; Blatz A; Peifer C; Halekotte J; Leban J; Vitt D; Holzmann K; Bakulev V; Pinna LA; Henne-Bruns D; Hillenbrand A; Kornmann M; Leithäuser F; Bischof J; Knippschild U
    Int J Cancer; 2015 Jun; 136(12):2799-810. PubMed ID: 25404202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p42.3: a promising biomarker for the progression and prognosis of human colorectal cancer.
    Yuan XS; Zhang Y; Guan XY; Dong B; Zhao M; Mao LL; Lu YY; Tian XY; Hao CY
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1211-20. PubMed ID: 23576022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.